Description / Table of Contents:
Role of P-glycoprotein for resistance of tumors to anticancer drugs: From bench to bedside -- Clinical relevance of multidrug-resistance-related proteins (MRPs) for anticancer drug resistance and prognosis -- Role of Breast Cancer Resistance Protein (BCRP, ABCG2) in Cancer Outcomes and Drug Resistance -- A new strategy of ALA-photodynamic cancer therapy: Inhibition of ABC transporter ABCG2 -- ABC transporters in cancer stem-like cells -- Radiopharmaceuticals for the imaging of ABC-transporter-mediated multidrug resistance in cancer -- Modulation of P-glycoprotein-mediated multidrug resistance by synthetic and phytochemical small molecules, monoclonal antibodies and therapeutic nucleic acids -- ABC transporter modulatory drugs from marine sources: A new approach to overcome drug resistance in cancer -- The role of ABC multidrug transporters in resistance to targeted anti-cancer kinase inhibitors -- Nanotechnology to combat multidrug resistance in cancer -- Drugs affecting epigenetic modifications of ABC transporters
This volume covers the most current topics relevant to ABC transporters and resistance to novel and established anticancer drugs, prognosis of patients to compounds to modulate multidrug resistance, compounds used in photodynamic therapy, tyrosine kinase inhibitors and others. Furthermore, the potential of radiopharmaceuticals for diagnosis of multidrug-resistant tumors is also discussed. The development of resistance is a major obstacle in cancer chemotherapy since decades. Drug resistance may develop during repeated treatment cycles after initially successful therapy (acquired or secondary resistance). Alternatively, tumors may be resistant from the beginning (inherent or primary resistance). The failure of chemotherapy is a major reason for the fatal outcome of tumor diseases in many patients. Even worse, tumors frequently develop not only resistance to single drugs, but also to many others at the same time. This phenomenon was termed multidrug resistance and decreases the success rates of therapy regimens with combinations of structurally and functionally different drugs. The uncommonly broad spectrum of anticancer agents that are transported by ABC transporters makes these proteins exquisite targets to search for compounds that inhibit their transport function. A huge amount of compounds from many pharmacologically established drug were observed to inhibit ABC transporters and to reverse multidrug resistance€”áll of these topics and more is explored in this volume
X, 300 p. 60 illus., 21 illus. in color. : online resource.